We have recently updated our Privacy Policy to include information regarding the cookies we collect. By continuing to use this website you agree to our Privacy Policy and Terms of Use.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 11, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced it will host a live webcast on Tuesday, August 6, 2019 at 8:00 a.m.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 3, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 1, 2019 , the Compensation Committee of Sage’s Board of
Event will provide an R&D and portfolio review across the depression, neurology and neuropsychiatric franchises CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 27, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 18, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the BMO Prescriptions for Success Healthcare
On track for full commercial launch in the U.S. in late June CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 14, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 5, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 3, 2019 , the Compensation Committee of Sage’s Board of
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Goldman Sachs 40 th Annual Global Healthcare
CAMBRIDGE, Mass --(BUSINESS WIRE)--May 14, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the 2019 RBC Capital Markets Global Healthcare
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Bank of America Merrill Lynch 2019 Health
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 6, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on May 1, 2019 , the Compensation Committee of Sage’s Board of
